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AbstrACt
Introduction Individualised treatment through therapeutic 
drug monitoring (TDM) may improve tuberculosis (TB) 
treatment outcomes but is not routinely implemented. 
Prospective clinical studies of drug exposure and minimum 
inhibitory concentrations (MICs) in multidrug-resistant 
TB (MDR-TB) are scarce. This translational study aims 
to characterise the area under the concentration–time 
curve of individual MDR-TB drugs, divided by the MIC 
for Mycobacterium tuberculosis isolates, to explore 
associations with markers of treatment progress and to 
develop useful strategies for clinical implementation of 
TDM in MDR-TB.
Methods and analysis Adult patients with pulmonary 
MDR-TB treated in Xiamen, China, are included. Plasma 
samples for measure of drug exposure are obtained at 0, 1, 
2, 4, 6, 8 and 10 hours after drug intake at week 2 and at 0, 
4 and 6 hours during weeks 4 and 8. Sputum samples for 
evaluating time to culture positivity and MIC determination 
are collected at days 0, 2 and 7 and at weeks 2, 4, 8 and 12 
after treatment initiation. Disease severity are assessed with 
a clinical scoring tool (TBscore II) and quality of life evaluated 
using EQ-5D-5L. Drug concentrations of pyrazinamide, 
ethambutol, levofloxacin, moxifloxacin, cycloserine, 
prothionamide and para-aminosalicylate are measured by 
liquid chromatography tandem-mass spectrometry and the 
levels of amikacin measured by immunoassay. Dried blood 
spot on filter paper, to facilitate blood sampling for analysis 
of drug concentrations, is also evaluated. The MICs of the 
drugs listed above are determined using custom-made broth 
microdilution plates and MYCOTB plates with Middlebrook 
7H9 media. MIC determination of pyrazinamide is performed 
in BACTEC MGIT 960.
Ethics and dissemination This study has been approved 
by the ethical review boards of Karolinska Institutet, 
Sweden and Fudan University, China. Informed written 
consent is given by participants. The study results will be 
submitted to a peer-reviewed journal.
trial registration number NCT02816931; Pre-results.
IntroduCtIon
Despite programmatic management of 
tuberculosis (TB), the incidence of multi-
drug-resistant TB (MDR-TB), defined as 
strengths and limitations of this study
 ► To our knowledge, this is a novel study approach 
which fully investigates the distribution of drug 
exposure in relation to minimum inhibitory con-
centration (MIC) for Mycobacterium tuberculosis 
(Mtb) isolates from patients with multidrug-resistant 
tuberculosis (TB) along with biomarkers (eg, time to 
positivity), culture conversion and the clinical scor-
ing tool TBscore II to assess treatment outcome.
 ► We used a translational approach with experts from 
research centres across the world to design a study 
protocol including both MIC  determinations, drug 
exposure estimation using novel technology, as well 
as microbiological and clinical surrogate markers for 
improvement, to enable strategies for therapeutic 
drug monitoring use in TB treatment.
 ► The patients’ drug exposure will be compared with 
individual Mtb MICs, exploring pharmacokinetics–
pharmacodynamics indices in multidrug-resistant 
TB treatment.
 ► Dried blood spot as a method to simplify blood sam-
pling by finger prick instead of venous sampling will 
be investigated.
 ► A limitation of the study is the low target number of 
patients for inclusion, due to a laborious and costly 
study protocol, which might partly be compensated 
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Mycobacterium tuberculosis (Mtb) resistant to rifampicin 
and isoniazid, is steadily increasing.1 Inconsistent treat-
ment, due to poor treatment adherence, lack of drugs, as 
well as subtherapeutic dosing are contributing factors. For 
many TB drugs, the administered dose is not predictive 
of the drug exposure and clinical effect in the patient.2 
A hollow-fibre study indicated that pharmacokinetic vari-
ability may be an underestimated cause of drug resistance 
development3 and low drug concentrations in the treat-
ment of drug-susceptible TB have been associated with 
poor outcome in some prospective studies.4 5 
Therapeutic drug monitoring (TDM) is a strategy to 
personalise treatment by measuring systemic drug levels 
in blood/plasma as a guide for individual dose adjust-
ments.6 Specifically for infectious diseases, the drug effi-
cacy not only depends on the drug exposure but also 
on the susceptibility level of the bacteria, the minimum 
inhibitory concentration (MIC).7 The MIC is defined as 
the lowest concentration of a drug that inhibits visible 
growth of bacilli and should be exceeded to cure the 
infection.8 TDM has been recommended during MDR-TB 
treatment by several organisations, for example, the 
Infectious Disease Society of America.9 The pharmacoki-
netic studies that have been performed have shown that 
subtherapeutic drug levels in TB treatment are common, 
although with conflicting results regarding association 
between drug exposure and treatment outcome.10–12 
However, studies on MDR-TB are limited and only a few 
studies have included drug concentrations as well as the 
individual MICs of the bacteria.13–15
An optimal estimation of drug exposure (ie, area under 
the concentration versus time curve (AUC)) traditionally 
requires multiple venous blood samples, often followed 
by prompt centrifugation and sample storage at −80°C. 
A simplified strategy for collection and transportation of 
blood samples needed for TDM would aid its implemen-
tation in clinical practice. Dried blood spot (DBS) allows 
minimal blood sampling by capillary finger pricking on 
filter paper, which can be transported without a cold 
chain, simplifying transportation and storage.16 DBS is a 
well-established and validated method, but has only been 
evaluated for a few second-line TB drugs, for example, 
moxifloxacin and linezolid.16–18 A clinical implemen-
tation of DBS could enable TDM for TB treatment in 
remote areas and reduce costs.16
There are scarce data regarding drug exposure and 
treatment outcome in MDR-TB treatment. Assessing 
end-of-treatment outcome in MDR-TB studies is cumber-
some due to long treatment durations. Other strategies 
include using interim endpoints such as time to positivity 
(TTP) in liquid culture media, a surrogate of bacteri-
cidal activity,19 and sputum culture conversion after 2 
or 3 months of treatment,20 the latter commonly used in 
drug efficacy studies. A clinical composite scoring system, 
TBscore II, can be used as a surrogate marker for TB 
disease severity and to predict failure.21 Patients’ quality of 
life can be objectified using the validated EQ-5D-5L tool 
assessing five different dimensions (mobility, self-care, 
typical activity, pain/discomfort and anxiety/depression), 
an often overlooked tool in clinical treatment studies.
China has the second highest burden of MDR-TB in the 
world and has existing resources to perform TDM, thus 
making it an ideal setting for pharmacokinetic/pharma-
codynamic (PK/PD) studies. The overall incidence of TB 
in China was 895 000 TB cases in 2017, of which 8.2% 
were MDR-TB.22
We describe a new comprehensive approach to TDM 
studies, assessing drug exposure, individual MICs as well 
as clinical outcome markers. The primary aim of the 
study is to investigate the distribution of AUC/MIC and 
Cmax/MIC for MDR-TB drugs during MDR-TB treatment 
in China. Secondary aims are to analyse AUC/MIC in 
relationship to markers of clinical improvement, such 
as sputum culture conversion, TTP, TBscore II, body 
mass index (BMI) and qualitative measures of well-being 
(European Quality of Life scale, EQ-5D-5L). Signs of 
acquired resistance are assessed by investigating changes 
in MICs and genetic mutations, during the first 3 months 
of treatment. A clinical implementation of DBS as well 
as a method of simultaneous MIC determination are 
assessed to simplify the use of TDM in clinical practice.
MEthods And AnAlysIs
study design
We are conducting a prospective cohort study of TB drug 
exposure and MICs in patients with MDR-TB in Xiamen, 
China. This is a joint project between the School of Public 
Health Fudan University Shanghai, Department of Medi-
cine Karolinska Institutet, Department of Pharmaceutical 
Biosciences University of Uppsala and the Public Health 
Agency of Sweden, in collaboration with the Centre for 
Disease Control (CDC) in Xiamen. The study protocol 
conforms with the Strengthening the Reporting of Obser-
vational Studies in Epidemiology Statement for cohort 
studies.23
Patient and public involvement
The original study protocol by the coauthors was changed 
by reducing the number of blood samples after feedback 
from patients included in a pilot study. The result of the 
study can be obtained in Mandarin on request at the 
Xiamen CDC. Patients were not involved in the recruit-
ment and the conduct of the study.
study setting
The study is carried out in Xiamen, Fujian region in 
Southeast China, where the incidence of TB in 2016 was 
42.4 cases/100 000 inhabitants and of the 1661 confirmed 
cases that year, there were 28 MDR-TB patients (1.7%).24
The study hospital is the designated TB hospital in Xin 
Ling, Xiamen, a large teaching hospital with a special-
ised TB ward with 105 beds as well as a negative pressure 
ward (12 beds) with specialised TB physicians and nurses. 
Recruitment of patients is performed by the Xiamen CDC, 
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admitted for 2 months of in-patient treatment. The study 
is registered at  ClinicalTrials. gov (NCT02816931) and 
opened on 17 April 2016.
study participants
A total number of 30 fully evaluable patients, according 
to the criteria below, will be included.
Inclusion criteria
 ► Consenting adults (≥18 years) with a verified diagnosis 
of pulmonary MDR-TB, by routine drug susceptibility 
testing (DST) admitted to the Xin Ling TB Hospital, 
Xiamen.




 ► HIV infection
 ► Patients admitted to the intensive care unit
 ► Confirmed extensively drug-resistant TB by DST
 ► Ongoing medication for MDR-TB (ie, five active drugs 
or more for more than 1 day.)
study outline
The overall study outline is shown in figure 1. After 
informed consent, a completed inclusion questionnaire 
with demographic and clinical information, baseline 
blood and sputum samples are collected from the patient 
by a designated study nurse. Treatment regimens adhere 
to WHO guidelines and are adjusted following DST 
results. The first day of MDR-TB treatment is defined 
as ‘day 0’. Clinical data are collected at inclusion, day 
2, weeks 1, 2, 4, 8 and week 12 after treatment initia-
tion. Adverse events, routine blood tests and vital signs 
are closely monitored to ensure the safety of the study 
patients. The final treatment outcome is recorded at the 
end of MDR-TB treatment.
Drug concentrations of second-line TB drugs are 
measured at steady state at 2, 4 and 8 weeks after treat-
ment initiation. In order to estimate the AUC, multiple 
blood samples for drug concentration analysis (ie, rich 
sampling) are collected at week 2 (0, 1, 2, 4, 6, 8 and 
10 hours after drug intake). A sparse-sampling strategy 
is applied at weeks 4 and 8 (0, 4 and 6 hours). Whole 
blood samples are simultaneously collected and pipetted 
directly onto DBS cards. Finger prick blood samples 
are collected on DBS cards at week 2 (0, 4 and 6 hours 
after drug intake) (figure 2). The drug concentrations 
in plasma and DBS will be analysed using liquid-chroma-
tography tandem mass spectrometry (LC-MS/MS) and 
immunoassay.25 In order to assess delayed absorption and 
possible interactions, information of concomitant drugs 
is noted in the medical records. Additionally, detailed 
food intake is noted by the patient in a diary on the days 
of blood sample collection. Pharmacometric modelling 
and simulation will be performed in the analysis phase.
Sputum is collected at days 0 and 2 and weeks 1, 2, 4, 
8 and 12 in order to evaluate changes in TTP. Whole 
genome sequencing (WGS) and MIC determination for 
TB drugs (pyrazinamide (PZA), ethambutol, levoflox-
acin, moxifloxacin, ofloxacin, cycloserine, ethionamide, 
para-aminosalicylic acid (PAS), amikacin, kanamycin, 
rifampicin and isoniazid) are performed at baseline and 
for any positive culture after 1 month or more of treat-
ment, to assess development of acquired resistance. Time 
to sputum culture conversion is defined as the day from 
starting treatment until the day of the first of two consec-
utive negative sputum cultures, collected at least 30 days 
apart.
Disease severity is estimated and monitored using 
inflammatory markers such as C reactive protein and 
erythrocyte sedimentation rate, presence of cavity on 
chest X-ray as well as the total score obtained in TBscore 
II, based on the following variables; cough, dyspnoea, 
chest pain, anaemia (pale lower conjunctivas), BMI and 
mid-upper arm circumference.21 Quality of life during 
the first 3 months of treatment is estimated using the vali-
dated EQ-5D-5L-5L (Mandarin version).26 The patients 
are followed up until treatment completion or loss to 
follow-up, whichever occurs first, through information 
accessible from the TB-registry, Xiamen CDC.
lAborAtory MEthods
drug concentration measurement
A combined assay for drug concentration analysis using 
LC-MS/MS is under development at the Xiamen CDC to 
measure the plasma concentrations of PZA, ethambutol, 
levofloxacin, moxifloxacin, cycloserine, prothionamide 
and PAS.27 28 The second-line injectable drug amikacin 
will be analysed with a commercial immunoassay kit 
(amikacin assay kit, Beckman Coultier). The collected 
venous blood samples will be centrifuged at 3500 rpm for 
10 min within 1 hour from sampling. Aliquots of plasma 
are then frozen at −70°C awaiting analysis.
A puncture from the DBS card will be immersed in 
extraction solution as previously described18 and anal-
ysed through LC-MS/MS. Plasma concentrations will be 
compared with blood concentrations collected by DBS.18
Microbiology: ttP, dst and MIC
All microbiological tests are carried out at a biosafety 
laboratory level 3 at the Xiamen CDC, apart from routine 
DST testing which is partly performed in local hospital 
laboratories and WGS analysis performed at the Public 
Health Agency of Sweden.
time to culture positivity
Sputum samples are treated according to Chinese National 
standards based on a WHO recommended protocol.29 In 
short, NALC-NaOH is added to the sputum, then shaken 
using a vortex shaker until fully liquefied, followed by 
incubation for 15 min in room temperature. Phosphate 
buffer is added to reach a total volume of 45 mL, after 
which the solution is centrifuged for 15 min at 3000 g. 
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added. Finally, 0.5 mL of the solution is transferred using 
a pipette to two labelled MGIT tubes, gently tilted for 
1 min and incubated in the BACTEC MGIT 960 machine 
at 37°C. TTP is done in duplicate and is automatically 
recorded by the BACTEC MGIT 960.
drug susceptibility testing
Routine DST is performed according to Chinese 
National Guidelines with the proportion method on 
Lowenstein-Jensen (LJ) medium, according to WHO’s 
recommendations.30
Figure 1 Study overview. Study patients are given a drug diary to record concomitant drugs and food intake during the 
first 12 weeks. Sputum samples are collected regularly during the study to assess time to positivity in BACTEC MGIT. Rich 
blood sampling is collected after 2 weeks of treatment and sparse blood sampling at week 6 and 8. Venous blood samples 
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simultaneous MIC determination of Mtb using trEK sensititre 
broth microdilution plates
Since MIC testing in BACTEC MGIT is labour-intense 
and time-consuming, a high throughput broth micro-
dilution plate has been developed to test up to 12 anti-
biotics simultaneously in Middlebrook 7H9 on a single 
MIC plate. We have designed a custom-made Sensititre 
plate for the drugs used at the study site, with concen-
tration ranges including wild-type isolates, manufac-
tured by Thermofisher (figure 3). The reference isolate 
H37Rv ATCC 27294 is always included in each test run 
and compared with previously published quality control 
target ranges for each drug.31 The Thermofisher Sensi-
titre MYCOTB plate is used for internal validation of 
ethionamide (range 0.5 mg/L–32 mg/L), which was 
not stable in the pretrial validation of the customised 
plate.
After positive culture of Mtb in the BACTEC MGIT 960 
and recording of TTP, the isolates are stored at −80°C 
awaiting MIC determination. After thawing and recul-
turing on LJ media, bacterial suspensions are prepared 
from Mtb isolates which are no more than 2 weeks old. 
Bacterial suspension together with Middlebrook 7H9 
stock solution are then added to each well, according to 
the manufacturer’s instructions.32 The plates are sealed 
and left to incubate in 37°C. Manual reading is done after 
10–21 days, depending on growth, assisted by an inverted 
mirror (figure 4).
Due to specific pH requirements, PZA susceptibility is 
determined using BACTEC MGIT 960 PZA Susceptibility 
Test, with a pH of 5.9 as previously described.33 In short, 
colonies of Mtb no older than 2 weeks are suspended in 
Middlebrook 7H9 broth with phosphate-buffered saline. 
A bacterial suspension, corresponding to a McFarland 
turbidity of 0.5, is prepared. Following the test protocol 
provided by the manufacturer (Becton Dickinson Biosci-
ences, Sparks, Maryland, USA), the suspension is there-
after diluted 1:5 (inoculum A), from which a 1:10 diluted 
control is prepared (inoculum B). From inoculums A and 
B, 0.5 mL is then added to the MGIT 960 PZA tubes and 
the proportional growth control tube, respectively. The 
tubes are incubated in 37°C and read automatically by the 
BACTEC MGIT.
Figure 3 Customised Sensititre broth microdilution plate (CML1FSWE). The wells are prefilled with antibiotics and Middlebrook 
7H9 in predetermined concentrations (mg/L) for minimum inhibitory concentration determination. AMI, amikacin; CAP, 
capreomycin; CYK, cycloserine; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KAN, kanamycin; LEVO, levofloxacin; 
MOXI, moxifloxacin; OFL, ofloxacin; PAS, para-aminosalicylic acid; PTH, prothionamide; RIF, rifampicin. 
Figure 2 Blood collected through finger prick onto dried 
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Whole genome sequencing
All baseline study isolates, as well as any viable isolate 
after at least 1 month of treatment or more, will be anal-
ysed using WGS to detect new resistance mutations. In 
brief, DNA is extracted from Mtb LJ cultures using a 
chloroform/CTAB (N-cetyl-N,N,N-trimethyl ammonium 
bromide)-based protocol,34 transported to Sweden and 
sequenced using Illumina technology (Illumina, San 
Diego, California, USA).
Mapping to a set of resistant genes from the Mtb 
H37Rv reference genome (GeneBank accession nr 
NC_000962.3) and extraction of variants are performed in 
CLC Genomics Workbench 8 (Qiagen, Hilden, Germany) 
using the following filters: minimum coverage: 10x; 
minimum count of reads calling variants: 2; minimum 
frequency of reads calling variants: 10%; minimum 
frequency of reads calling variants in each direction: 5%. 
In addition, pyro-error variants in homopolymer regions 
with a minimum length of 3 and a frequency below 0.8 
are removed. The remaining variants are then compared 
with our in-house database of resistance mutations.
data analysis plan
Regular study monitoring is performed quarterly by 
the Swedish and Chinese researchers as well as biweekly 
reports from the study site. Study data from the case 
report forms are entered in EpiData with a range check 
by two independent researchers and results compared for 
coherence.
The distribution of AUC/MIC and Cmax/AUC will 
be presented and visualised in graphs. The agreement 
between drug exposure in plasma and DBS will be 
assessed. An exploratory analysis of the PK/PD indices 
for key TB drugs, such as fluoroquinolones, in relation to 
sputum culture conversion, TTP and changes in TBscore 
II during treatment will be performed. Pharmacometric 
modelling will assess the relationship between dose, 
concentrations and effect and population models will 
be applied, using the non-linear mixed-effects model-
ling software NONMEM (Icon Development Solutions, 
Ellicot city). Time-to-event data with censoring will be 
analysed using the Cox regression model, whereas binary 
outcomes will be analysed with logistic regression and 
continuous outcome with linear regression, if data are 
normally distributed. The validated Chinese value set of 
the quality of life tool EQ-5D-5L will be used and quality 
of life perception described.
For analysis of trends in drug exposure over time, the 
dependent nature of the data will be taken into account 
using mixed-effect models. Missing values will not be 
imputated. A p value of <0.05 will be considered as statis-
tically significant.
Information of potential confounders such as age, 
gender, BMI, concomitant treatment and comorbidities 
and disease severity assessed by TBscore II will be collected 
and evaluated during data analysis. As this is a feasibility 
and hypothesis-generating study, no power calculation 
was performed.
Ethics and dissemination
The study is performed in accordance with Good Clinical 
Practice and the Declaration of Helsinki. Ethical approval 
was obtained.
Prior to the study start, a designated study team of 
nurses, doctors and laboratory staff participated in 
training workshops of the study protocol and ethical 
considerations, led by the main study investigators from 
Fudan University and Karolinska Institutet. Patients are 
informed about the study orally and in writing, including 
information that neither study participation nor study 
termination will result in any changes in their treatment. 
An informed consent is signed or, in the case of illiteracy, 
a fingerprint given under observation by a witness. A 
travel grant to enable follow-up is offered to all the study 
participants. The sum was set so as not to create financial 
motivation to accept study participation. All patients are 
treated according to standard of care at the designated 
MDR-TB hospital and patients’ safety ensured by regular 
monitoring.
Extensive blood sampling is a sensitive issue in China 
and should be avoided in severely ill patients. There-
fore, the number of blood samples collected have been 
reduced to a minimum for the estimation of the AUC. 
Moreover, extensive blood sampling should be mini-
mised in severely ill patients. An intravenous line is 
inserted to minimise patient discomfort. The increased 
sputum sample collection is a potential hazardous risk for 
other patients, hospital and laboratory staff. Therefore, 
biosafety and awareness training, as well as an upgrade of 
biosafety equipment, have been implemented.
dissemination
We aim to present our data in international conferences 
and to publish our results in a peer-reviewed journal, 
Figure 4 Example of minimum inhibitory concentration 
(MIC) determination using microdilution plate. The red ring 
denotes the first well of amikacin (AMI) with no visible growth, 
that is, the MIC of AMI of this Mycobacterium tuberculosis 
isolates is 1 mg/L. Please refer to Figure 3 for plate lay-out. 
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regardless of study results. Any significant protocol 
amendments will be reported to the respective ethical 
boards in Sweden and China.
dIsCussIon
In this prospective observational cohort study, we present a 
comprehensive, translational approach to TDM studies in 
MDR-TB, likely to be of benefit in future trials in the area. 
Multiple blood sampling and individual MIC determina-
tion will enable exploration of AUC/MIC for MDR-TB 
drugs, a poorly investigated research area. In a key study, 
the level of peak drug concentrations and AUC of PZA, 
rifampicin and isoniazid strongly influenced treatment 
outcome, although no comparison with the Mtb MICs was 
performed.4 Bacterial MIC has also been found to influ-
ence treatment outcome of patients with MDR-TB, with 
a sixfold increased odds of failure when comparing MIC 
of gatifloxacin of ≤0.25 mg/L to 1 mg/L, although both 
concentrations are still regarded as susceptible.35 There 
are very few tentative targets for most second-line TB 
drugs, although an AUC/MIC >100 for fluoroquinolones 
has been suggested.36 So far, the tentative targets have not 
been correlated with clinical outcome. To our knowledge, 
this is the first study to assess both AUCs and individual 
MICs for the most commonly used second-line drugs in 
MDR-TB regimen.
Not only have optimal PK/PD targets not been estab-
lished, the critical concentrations used for DST are poorly 
validated.37 MIC determination provides more informa-
tion of the level of the resistance, but it has the drawback 
of being time-consuming. Fortunately, commercial MIC 
plates are available, facilitating fast MIC determination 
and will be assessed in this study.38 When interpreting 
individual MICs, the clinician should bear in mind the 
innate variability may be up to ±1 twofold MIC dilution 
step, but often less in a meticulous laboratory, which 
impacts on PK/PD indices estimates. Furthermore, when 
results of MIC testing are reported, it is important to note 
that there is no reference method for MIC testing of Mtb.
A limitation of this study protocol is the limited target 
number of included patients, common with other studies 
in the field, mainly due to MDR-TB incidence in Xiamen 
and costly and cumbersome sampling procedures. This 
may not allow us to perform extensive analysis of PK/PD 
indices in relation to treatment outcome, especially since 
all patients are treated with multiple drugs. However, 
pharmacometric mathematical modelling and simula-
tion enables reduced sample sizes in clinical trials39 and 
may partly compensate for the limited number of study 
patients in our study. Also, we use markers of early clinical 
improvement using microbiological surrogate measure-
ments, such as TTP and sputum culture conversion, due 
to the nature of long treatment periods and follow-up. 
Sputum culture conversion is an imperfect surrogate 
marker of the final treatment outcome but it is, never-
theless, commonly used in clinical trials and is a sign of 
clinical improvement.40
This study will provide useful insights of the PK/
PD relations in MDR-TB treatment and highlight the 
importance of individualised treatment, taking both 
drug concentrations and MICs and innovative surrogate 
markers of improvement into account. With a simulta-
neous method for drug concentration analysis and blood 
sample collection simplified through DBS, TDM would be 
more feasible in clinical practice, including low-resource 
and high-endemic settings. We hope that this study will 
inspire future randomised controlled studies for TDM 
for both drug susceptible and MDR-TB, including treat-
ment groups such as children, pregnant women, diabetic 
and HIV-infected patients who are prone to altered PK 
characteristics.
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